Skip to main content
SpringerLink
Log in

Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The present study was conducted to describe antipsychotic (AP) prevalent and incident use, characteristics of AP users, and their trends in the French population.

Methods

A cross-sectional study was repeated yearly from January 1, 2007 to December 31, 2013 (for prevalence analysis) or to December 31, 2012 (for incidence analysis) using the French Health Insurance reimbursement database (Echantillon Généraliste de Bénéficiaires, EGB). For each year studied, prevalent and incident AP users were described in terms of age and gender overall, and according to the type of AP (FGAPs or SGAPs) used at index date. In addition, concurrent medications and comorbidities that a priori contraindicate the use of drugs having atropinic properties were researched.

Results

Prevalence and incidence remained relatively stable along the 2007–2013 period. Trends slightly decreased, from 2.07% (n = 10,252) to 2.05% (n = 11,015) for prevalence, and from 0.73% (n = 3461) to 0.66% (n = 3363) for incidence, especially in elderly, in contrast of children and adolescents (+ 39% for prevalence, from 184 to 271). The number of coprescribed drugs was found high (median = 5) and remained constant over time. In 2013, about 7% of prevalent AP users presented with a comorbidity increasing the risk of atropinic ADRs, and 36% used at least one concurrent atropinic drug. In incident AP users, these numbers were of 8 and 29%, respectively.

Conclusions

The present study highlighted a marked shift from FGAPs toward SGAPs, as well as an increase in AP use in children and adolescents in France.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Rang HP, Dale MM, Ritter JM et al (2011) Rang & Dale’s Pharmacology, 7th edn. Churchill Livingstone, London

    Google Scholar 

  2. Cáceres MC, Peñas-Lledó EM, de la Rubia A et al (2008) Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. Eur J Clin Pharmacol 64(1):73–76. https://doi.org/10.1007/s00228-007-0386-1

    Article  PubMed  Google Scholar 

  3. Verdoux H, Tournier M, Bégaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121(1):4–10. https://doi.org/10.1111/j.1600-0447.2009.01425.x

    Article  CAS  PubMed  Google Scholar 

  4. Moncrieff J (2013) Magic bullets for mental disorders: the emergence of the concept of an ‘antipsychotic’ drug. J Hist Neurosci 22(1):30–46. https://doi.org/10.1080/0964704X.2012.664847

    Article  PubMed  PubMed Central  Google Scholar 

  5. Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy P, Favre J, Simon N, Bordet R, Rolland B (2015) Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des 21(23):3280–3297. https://doi.org/10.2174/1381612821666150619092903

    Article  CAS  PubMed  Google Scholar 

  6. Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L (2015) French health insurance databases: what interest for medical research? Rev Med Interne 36(6):411–417. https://doi.org/10.1016/j.revmed.2014.11.009

    Article  CAS  PubMed  Google Scholar 

  7. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y (2010) French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 58(4):286–290. https://doi.org/10.1016/j.respe.2010.04.005

    Article  CAS  PubMed  Google Scholar 

  8. Aging Brain Care. Anticholinergic Cognitive Burden Scale—2012 Update. Available: www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf

  9. Laroche ML, Charmes JP, Bouthier F, Merle L (2009) Inappropriate medications in the elderly. Clin Pharmacol Ther 85(1):94–97. https://doi.org/10.1038/clpt.2008.214

    Article  CAS  PubMed  Google Scholar 

  10. Ilyas S, Moncrieff J (2012) Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry 200(5):393–398. https://doi.org/10.1192/bjp.bp.111.104257

    Article  PubMed  Google Scholar 

  11. Nguyen TTH, Pariente A, Montastruc J-L, et al. An original pharmacoepidemiologic - pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol Published Online First: 30 September 2016. https://doi.org/10.1111/bcp.13145

  12. Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M (2015) Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol 25(10):1556–1565. https://doi.org/10.1016/j.euroneuro.2015.07.010

    Article  CAS  PubMed  Google Scholar 

  13. Moncrieff J (2014) The medicalisation of ‘ups and downs’: the marketing of the new bipolar disorder. Transcult Psychiatry 51(4):581–598. https://doi.org/10.1177/1363461514530024

    Article  PubMed  Google Scholar 

  14. Healy D (2006) The latest mania: selling bipolar disorder. PLoS Med 3(4):e185. https://doi.org/10.1371/journal.pmed.0030185

    Article  PubMed  PubMed Central  Google Scholar 

  15. Jones DR, Macias C, Barreira PJ, Fisher WH, Hargreaves WA, Harding CM (2004) Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv 55(11):1250–1257. https://doi.org/10.1176/appi.ps.55.11.1250

    Article  PubMed  PubMed Central  Google Scholar 

  16. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N (2007) Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 116(5):317–333. https://doi.org/10.1111/j.1600-0447.2007.01095.x

    Article  CAS  PubMed  Google Scholar 

  17. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65(10):1377–1388. https://doi.org/10.4088/JCP.v65n1013

    Article  PubMed  Google Scholar 

  18. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321(7273):1371–1376. https://doi.org/10.1136/bmj.321.7273.1371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Peluso MJ, Lewis SW, Barnes TRE, Jones PB (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 200(5):387–392. https://doi.org/10.1192/bjp.bp.111.101485

    Article  PubMed  Google Scholar 

  20. Hugenholtz GWK, Heerdink ER, Stolker JJ, Meijer WE, Egberts ACG, Nolen WA (2006) Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 67(06):897–903. https://doi.org/10.4088/JCP.v67n0606

    Article  CAS  PubMed  Google Scholar 

  21. Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011) Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8(5):e1000434. https://doi.org/10.1371/journal.pmed.1000434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Verdoux H, Pambrun E, Cortaredona S, Tournier M, Verger P (2015) Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. Eur Child Adolesc Psychiatry 24(10):1181–1191. https://doi.org/10.1007/s00787-014-0668-y

    Article  PubMed  Google Scholar 

  23. Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V (2014) Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol 24(1):95–104. https://doi.org/10.1016/j.euroneuro.2013.09.003

    Article  CAS  PubMed  Google Scholar 

  24. Vinogradov S, Fisher M, Warm H et al (2009) The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 166(9):1055–1062. https://doi.org/10.1176/appi.ajp.2009.09010017

    Article  PubMed  PubMed Central  Google Scholar 

  25. Brébion G, Bressan RA, Amador X et al (2004) Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 34(2):369–374. https://doi.org/10.1017/S0033291703008900

    Article  PubMed  Google Scholar 

  26. Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D (2016) Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophr Res Treatment 2016:8213165. https://doi.org/10.1155/2016/8213165

    Article  PubMed  PubMed Central  Google Scholar 

  27. Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M (2016) Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol 30(6):616–624. https://doi.org/10.1111/fcp.12214

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The present study is part of the Drugs Systematized Assessment in real-liFe Environment (DRUGS-SAFE) research programme. This programme aims at providing an integrated system allowing the concomitant monitoring of drug use and drug safety in France. It is funded by the French Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). This publication represents the views of the authors and does not necessarily that of the ANSM.

Author information

Authors and Affiliations

  1. Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, University Bordeaux, F-33000, Bordeaux, France

    François Montastruc, Anne Bénard-Laribière, Pernelle Noize, Elodie Pambrun, Fabienne Diaz-Bazin, Marie Tournier, Bernard Bégaud & Antoine Pariente

  2. Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d’Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire, Toulouse, France

    François Montastruc

  3. CHU Bordeaux, Pole de Santé Publique, Centre Régional de Pharmacovigilance de Bordeaux, Service de Pharmacologie Médicale, F-33000, Bordeaux, France

    Anne Bénard-Laribière, Pernelle Noize, Bernard Bégaud & Antoine Pariente

Authors
  1. François Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Bénard-Laribière
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pernelle Noize
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elodie Pambrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabienne Diaz-Bazin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marie Tournier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bernard Bégaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antoine Pariente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Montastruc.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Table S1

(DOCX 12 kb)

Table S2

(DOCX 16 kb)

Table S3

(DOCX 15 kb)

Figure S1

(DOCX 39 kb)

Figure S2

(DOCX 26 kb)

Figure S3

(DOCX 39 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Montastruc, F., Bénard-Laribière, A., Noize, P. et al. Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol 74, 619–626 (2018). https://doi.org/10.1007/s00228-017-2406-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-017-2406-0

Keywords

Search

Navigation